Welcome to Ensem Theraputics
Kinetic Ensemble
for Precision Medicine
for Precision Medicine
TM
Who We Are
ENSEM Therapeutics (“ENSEM”) is a Boston-based, preclinical stage biopharmaceutical company focused on
high value and difficult-to-drug
targets in oncology to address unmet medical needs. The name ENSEM symbolizes innovations via the
integration of groundbreaking technologies
to decipher structural ENSEMbles and kinetics for drug design. The company’s mission is to discover,
develop, and commercialize transformative
oncology therapies for patients, while leading the advancement of AI-driven structural ensemble and
computational drug design.
Cryptic binding pockets: A small molecule (yellow) induces protein conformational changes (blue)
and the opening of a cryptic pocket.
Our Mission is to expand the universe of druggable targets to discover transformative
therapies for PATIENTS
Expand The Universe of Druggable targets via AI-powered Kinetic Ensemble TM
ENSEM develops and leverages Artificial Intelligence-powered structural Kinetic Ensemble
TM platform to discover cryptic pockets of traditionally undruggable targets,
offering new opportunities for
therapeutic intervention.
Dedicated to precision medicines
ENSEM leverages big data with advanced modeling and analytics to pioneer breakthrough precision
therapies for genetically defined diseases,
with Oncology as our initial focus.
We are owners driven to innovate and blaze new trails with urgency. We are bold in scope and
optimistic in spirit. We embrace challenges
with tenacity and hope.
We pursue our mission with passion and unwavering resolve. We make strategic choices and move forward
with the best ideas to discover
transformative medicines.
We do what’s right for our patients. We follow the science and act with integrity, care & humility. We
are disciplined and rigorous;
empowered and accountable for our actions.
We are a high performing, diverse and inclusive team. We build open and honest relationships. We speak
our mind and make it safe for others
to do so.